« | Home | »

New Drug Reduces Treatment-Resistant Migraine by Half

By jeremyc | April 19, 2018

Millions of people worldwide live with migraine, a painful neurological condition that has no cure as of yet. Making the matter worse is the fact that in many cases, migraine sufferers fail to get any help from treatments. Now there’s some good news for these people.

Researchers recently tested a new drug and found that it was effective in reducing migraine attacks in people with treatment-resistant migraine. The name of the new drug is erenumab.

These findings will give fresh hope to more than 35 million migraine sufferers in the U.S. The duration and frequency of migraine attacks vary from person to person. Usually a migraine episode might last between four to seventy-two hours. More often than not, migraine pain comes with other symptoms, like vomiting, numbness in feet or hands, visual impairment, and dizziness.

There are more than four million chronic daily migraine sufferers in the U.S. When a person has a migraine attack on 15 days a month or more on a regular basis, he or she is said to suffer from chronic daily migraine.

In this study, the researchers enrolled 246 individuals, each having treatment-resistant migraine. The drug erenumab was able to reduce migraine attacks by 50 percent in 30 percent of people who took it.

Topics: | Migraine/Headache | No Comments »

Comments are closed.